Javascript must be enabled to continue!
In silico identification of vaccine targets for 2019-nCoV
View through CrossRef
Background:
The newly identified coronavirus known as 2019-nCoV has posed a serious global health threat. According to the latest report (18-February-2020), it has infected more than 72,000 people globally and led to deaths of more than 1,016 people in China.
Methods:
The 2019 novel coronavirus proteome was aligned to a curated database of viral immunogenic peptides. The immunogenicity of detected peptides and their binding potential to HLA alleles was predicted by immunogenicity predictive models and NetMHCpan 4.0.
Results:
We report
in silico
identification of a comprehensive list of immunogenic peptides that can be used as potential targets for 2019 novel coronavirus (2019-nCoV) vaccine development. First, we found 28 nCoV peptides identical to Severe acute respiratory syndrome-related coronavirus (SARS CoV) that have previously been characterized immunogenic by T cell assays. Second, we identified 48 nCoV peptides having a high degree of similarity with immunogenic peptides deposited in The Immune Epitope Database (IEDB). Lastly, we conducted a
de novo
search of 2019-nCoV 9-mer peptides that i) bind to common HLA alleles in Chinese and European population and ii) have T Cell Receptor (TCR) recognition potential by positional weight matrices and a recently developed immunogenicity algorithm, iPred, and identified in total 63 peptides with a high immunogenicity potential.
Conclusions:
Given the limited time and resources to develop vaccine and treatments for 2019-nCoV, our work provides a shortlist of candidates for experimental validation and thus can accelerate development pipeline.
Title: In silico identification of vaccine targets for 2019-nCoV
Description:
Background:
The newly identified coronavirus known as 2019-nCoV has posed a serious global health threat.
According to the latest report (18-February-2020), it has infected more than 72,000 people globally and led to deaths of more than 1,016 people in China.
Methods:
The 2019 novel coronavirus proteome was aligned to a curated database of viral immunogenic peptides.
The immunogenicity of detected peptides and their binding potential to HLA alleles was predicted by immunogenicity predictive models and NetMHCpan 4.
Results:
We report
in silico
identification of a comprehensive list of immunogenic peptides that can be used as potential targets for 2019 novel coronavirus (2019-nCoV) vaccine development.
First, we found 28 nCoV peptides identical to Severe acute respiratory syndrome-related coronavirus (SARS CoV) that have previously been characterized immunogenic by T cell assays.
Second, we identified 48 nCoV peptides having a high degree of similarity with immunogenic peptides deposited in The Immune Epitope Database (IEDB).
Lastly, we conducted a
de novo
search of 2019-nCoV 9-mer peptides that i) bind to common HLA alleles in Chinese and European population and ii) have T Cell Receptor (TCR) recognition potential by positional weight matrices and a recently developed immunogenicity algorithm, iPred, and identified in total 63 peptides with a high immunogenicity potential.
Conclusions:
Given the limited time and resources to develop vaccine and treatments for 2019-nCoV, our work provides a shortlist of candidates for experimental validation and thus can accelerate development pipeline.
Related Results
In silico elucidation revealed SARS CoV and MERS CoV Drug Compounds could be Potential Therapeutic Candidates against Post Fusion Core (S2) Protein of Novel Coronavirus (2019-nCov)
In silico elucidation revealed SARS CoV and MERS CoV Drug Compounds could be Potential Therapeutic Candidates against Post Fusion Core (S2) Protein of Novel Coronavirus (2019-nCov)
Abstract
Novel coronavirus (2019-nCoV), since its emergence from Wuhan China in December 31, 2019 is still uncontrolled and has raised attention around the globe. According...
Burden of the Beast
Burden of the Beast
Introduction
Throughout the COVID-19 pandemic, and its fluctuating waves of infections and the emergence of new variants, Indigenous populations in Australia and worldwide have re...
In-silico Immunomodelling of 2019-nCoV
In-silico Immunomodelling of 2019-nCoV
Abstract
Background: Novel Corona Virus 2019 (2019-nCoV) is a positive-sense single-strand RNA virus form coronaviridae family, responsible for corona virus infectious dise...
Immunogenicity and adverse events of priming with inactivated whole SARS-CoV-2 vaccine (CoronaVac) followed by boosting the ChAdOx1 nCoV-19 vaccine
Immunogenicity and adverse events of priming with inactivated whole SARS-CoV-2 vaccine (CoronaVac) followed by boosting the ChAdOx1 nCoV-19 vaccine
Abstract
Background
Responding to SARS-CoV-2 Delta variants escaped the vaccine-induced immunity and waning immunity from the i...
Safety and Immunogenicity of a Booster SARS-Cov-2 Vaccination in Patients with Chronic Liver Disease
Safety and Immunogenicity of a Booster SARS-Cov-2 Vaccination in Patients with Chronic Liver Disease
ABSTRACT
This article is aim to investigate the safety and immunogenicity of the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) vaccine booster in pat...
Measles Vaccination Coverage and Protective Effectiveness in the Amhara Regional State, Ethiopia, 2019-2024
Measles Vaccination Coverage and Protective Effectiveness in the Amhara Regional State, Ethiopia, 2019-2024
Abstract
Background:
Despite the availability of an effective vaccine, measles remains a major public health problem in Ethiopi...
Therapeutic Options for the Treatment of 2019-Novel Coronavirus in
India: A Review
Therapeutic Options for the Treatment of 2019-Novel Coronavirus in
India: A Review
Purpose:
As of from 30 Jan to 31 May, 2020, more than 182,143 confirmed cases reported in India along with
86,984 recovered cases and 5164 deceased cases of COVID-19. More than 53 ...
Lectin-like Intestinal Defensin Inhibits 2019-nCoV Spike binding to ACE2
Lectin-like Intestinal Defensin Inhibits 2019-nCoV Spike binding to ACE2
Abstract
The burgeoning epidemic caused by novel coronavirus 2019 (2019-nCoV) is currently a global concern. Angiotensin-converting enzyme-2 (ACE...

